Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium+Olodaterol vs Fluticasone+Salmeterol in COPD
NCT01969721Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of tiotropium, olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Oct 2013; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01969721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969721.